BBR3464

Jump to: navigation, search

WikiDoc Resources for BBR3464

Articles

Most recent articles on BBR3464

Most cited articles on BBR3464

Review articles on BBR3464

Articles on BBR3464 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on BBR3464

Images of BBR3464

Photos of BBR3464

Podcasts & MP3s on BBR3464

Videos on BBR3464

Evidence Based Medicine

Cochrane Collaboration on BBR3464

Bandolier on BBR3464

TRIP on BBR3464

Clinical Trials

Ongoing Trials on BBR3464 at Clinical Trials.gov

Trial results on BBR3464

Clinical Trials on BBR3464 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on BBR3464

NICE Guidance on BBR3464

NHS PRODIGY Guidance

FDA on BBR3464

CDC on BBR3464

Books

Books on BBR3464

News

BBR3464 in the news

Be alerted to news on BBR3464

News trends on BBR3464

Commentary

Blogs on BBR3464

Definitions

Definitions of BBR3464

Patient Resources / Community

Patient resources on BBR3464

Discussion groups on BBR3464

Patient Handouts on BBR3464

Directions to Hospitals Treating BBR3464

Risk calculators and risk factors for BBR3464

Healthcare Provider Resources

Symptoms of BBR3464

Causes & Risk Factors for BBR3464

Diagnostic studies for BBR3464

Treatment of BBR3464

Continuing Medical Education (CME)

CME Programs on BBR3464

International

BBR3464 en Espanol

BBR3464 en Francais

Business

BBR3464 in the Marketplace

Patents on BBR3464

Experimental / Informatics

List of terms related to BBR3464


Overview

Skeletal formula of BBR3464

BBR3464 (rINN: triplatin tetranitrate) is a new platinum-based cytotoxic drug that is currently undergoing clinical trials throughout the world for the treatment of human cancer. It is a trinuclear platinum coordination complex, with chloride and amine ligands. The drug acts by forming coordinate covalent adducts with cellular DNA, preventing DNA transcription and replication, and through this inducing apoptosis. BBR3464 is structurally similar to, but in a different family from, the anticancer drugs cisplatin, carboplatin and oxaliplatin.

History

BBR3464 was invented by Professor Nicholas Farrell at Virginia Commonwealth University in the United States. The development of this drug came from his earlier work looking at dinuclear platinum derivatives of cisplatin, research he began in the late 1980s. Similar work was also being undertaken by Dr John Broomhead at the Australian National University in Australia. BBR3464 was patented in the mid-1990s and was originally licensed to the pharmaceutical company Roche. In preclinical trials, BBR3464 demonstrated cytotoxic activity in cancer cell lines which have either intrinsic or acquired resistance to cisplatin. On this basis it entered Phase I (Toxicity) clinical trials under the auspices of Novuspharma before the rights were transferred to Cell Therapeutics.

This drug is currently undergoing Phase II (Efficacy) trials with mixed results. So far trials of the drug with patients suffering from ovarian cancer, small cell lung cancer and gastric or gastro-oesophageal adenocarcinomas have been reported in the literature.

Mode of action

The main target of BBR3464 is cellular DNA, similar to cisplatin. Outside of the cell, the concentration of chloride (approx. 100 millimolar) prevents the drugs from hydrolysing, but once inside the cell, where the concentration of chloride drops to between 4 and 20 millimolar, the chloride ligands of BBR3464 come off and the drug is capable of forming coordinate covalent bonds with purine bases on DNA. The novel adducts BBR3464 forms with DNA are though to be the mechanism by which this drug acts; the adducts are able to prevent DNA transcription and replication, thus inducing cell apoptosis.

Side-effects

All platinum based drugs, and particularly BBR3464, cause large dose limiting side-effects. For BBR3464 these are largely diarrhoea, cramps and vomiting, but are so severe that the maximum tolerated dose (MTD) in humans is between 0.9 to 1.1 milligrams per square metre. This is considerably lower than the MTD for all the platinum based drugs currently used in the clinic, like cisplatin (60–120 mg) and carboplatin (approx. 800 mg).

References

  • Wheate, Nial J. and Collins, J. Grant (2003). Multi-nuclear platinum complexes as anti-cancer drugs. Coord Chem Rev, 241, 133–145. doi:10.1016/S0010-8545(03)00050-X.
  • Wheate, Nial J. and Collins, J. Grant (2005). Multi-nuclear platinum drugs: A new paradigm in chemotherapy. Curr Med Chem Anticancer Agents, 5, 267–279. PMID 15992354.





Linked-in.jpg